Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story

2 hours ago 1

Jonathan Ponciano, The Motley Fool

Sat, December 27, 2025 astatine 1:23 PM CST 5 min read

Prague-based Pale Fire Capital SE added 639,162 shares of Teva successful the 3rd quarter.
The wide presumption worth accrued by $16.53 cardinal from the erstwhile period.
As of September 30, the money reported holding astir 1.7 cardinal Teva shares valued astatine $34.13 million.
These 10 stocks could mint the adjacent question of millionaires ›

Prague-based Pale Fire Capital SE accrued its involvement successful Teva (NYSE:TEVA) by 639,162 shares during the 3rd quarter, adding astir $16.53 cardinal successful worth arsenic disclosed successful its November 13 SEC filing.

Pale Fire Capital SE disclosed successful a November 13 SEC filing that it accrued its holding successful Teva (NYSE:TEVA) by 639,162 shares during the 3rd quarter. The post-transaction holding reached astir 1.7 cardinal shares valued astatine $34.13 cardinal arsenic of September 30.

Teva present represents 3.74% of Pale Fire Capital SE’s 13F assets.

Top holdings aft the filing:

NYSEMKT: BTG: $247.58 cardinal (27.1% of AUM)
NASDAQ: GRPN: $237.73 cardinal (26.1% of AUM)
NYSE: DOLE: $115.42 cardinal (12.7% of AUM)
NYSE: IAG: $50.83 cardinal (5.6% of AUM)
NYSEMKT: NGD: $44.60 cardinal (4.9% of AUM)

As of Friday, Teva shares were priced astatine $31.89, up 41% implicit the past twelvemonth and good outperforming the S&P 500, which is up astir 15% successful the aforesaid period.

Metric

Value

Revenue (TTM)	$16.78 billion
Net Income (TTM)	$713.00 million
Price (as of Friday)	$31.89
One-Year Price Change	41%

Teva offers a wide portfolio of generic medicines, specialty pharmaceuticals, and biopharmaceutical products, including treatments for cardinal tense strategy disorders, respiratory diseases, oncology, and symptom management.
The institution operates a diversified concern exemplary focused connected developing, manufacturing, and distributing pharmaceuticals globally, with gross generated from some generic and specialty cause sales.
It serves healthcare providers, hospitals, pharmacies, and wholesalers successful North America, Europe, and planetary markets.

Teva is simply a starring planetary pharmaceutical institution specializing successful generic and specialty medicines. With a beardown beingness successful aggregate therapeutic areas and a wide planetary footprint, the institution leverages its standard and probe capabilities to present affordable healthcare solutions. Teva's diversified merchandise basal and established organisation channels supply a competitory vantage successful serving the needs of healthcare systems worldwide.

After crashing arsenic overmuch arsenic 90% oregon so, Teva is nary longer priced similar a breached pharmaceutical giant, but it is inactive trading astatine a steep discount to its ain past, with shares astir 55% beneath their 2015 highs adjacent aft a beardown year. That spread is the accidental semipermanent investors mightiness beryllium consenting to fill. Operationally, the communicative has stabilized. Teva’s third-quarter results showed continued advancement connected margins and currency generation, supported by outgo subject and dependable request crossed its generic and specialty portfolio. Net indebtedness has travel down materially implicit the past fewer years, easing the balance-sheet unit that erstwhile defined the carnivore case.

As portion of the broader portfolio, this presumption sits alongside holdings successful golden miners, user turnarounds, and profoundly discounted planetary equities, suggesting a portfolio built astir betterment narratives alternatively than momentum chasing. Teva fits that mold precisely. Ultimately, it appears this is not a stake connected explosive growth, but connected durability and re-rating. If Teva tin support executing and defending currency flows, today’s valuation whitethorn inactive understate what a repaired pharmaceutical incumbent is worthy implicit a afloat cycle.